# KEYNOTE-185 (NCT02579863)

> Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02579863
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Multiple Myeloma
- Interventions: Pembrolizumab; Lenalidomide; Dexamethasone
- Enrollment: 310
- Primary outcome: Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review

## Indexed commentary on KEYNOTE-185 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-185-nct02579863